ResMed Inc. (RMD)
NYSE: RMD · Real-Time Price · USD
234.14
-1.74 (-0.74%)
Apr 28, 2025, 4:00 PM EDT - Market closed
ResMed Revenue
ResMed had revenue of $1.29B in the quarter ending March 31, 2025, with 7.92% growth. This brings the company's revenue in the last twelve months to $5.02B, up 9.54% year-over-year. In the fiscal year ending June 30, 2024, ResMed had annual revenue of $4.69B with 10.95% growth.
Revenue (ttm)
$5.02B
Revenue Growth
+9.54%
P/S Ratio
6.85
Revenue / Employee
$503,159
Employees
9,980
Market Cap
34.33B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 4.69B | 462.30M | 10.95% |
Jun 30, 2023 | 4.22B | 644.87M | 18.02% |
Jun 30, 2022 | 3.58B | 381.30M | 11.93% |
Jun 30, 2021 | 3.20B | 239.81M | 8.11% |
Jun 30, 2020 | 2.96B | 350.44M | 13.44% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
RMD News
- 4 days ago - ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast - Benzinga
- 5 days ago - ResMed: Cornering The Market In Sleep Solutions - Seeking Alpha
- 5 days ago - ResMed Inc. (RMD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - ResMed slightly beats quarterly profit estimates on sleep devices demand - Reuters
- 5 days ago - Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025 - GlobeNewsWire
- 7 days ago - Resmed Names Salli Schwartz as Chief Investor Relations Officer - GlobeNewsWire
- 25 days ago - Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US - GlobeNewsWire
- 26 days ago - Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025 - GlobeNewsWire